DaVita (DVA)
NYSE: DVA · Health Care Services · Denver, CO
Our rating: Positive
Positive reaffirmed at $187.50, moderate conviction, October 30, 2026.
Breaks if: The positive view breaks if reported free cash flow for FY2027 comes in below $1.0B — roughly 25% below the current $1.3B level — as that would signal that reimbursement pressure or rising operating costs are compressing the cash engine faster than top-line growth can offset, invalidating the core FCF-yield thesis. On price, if the stock cannot hold above $150 over the next twelve months without a recovery in FCF expectations, the valuation cushion that underpins the call has closed.
Key figures
| Market value | $10.1B |
|---|---|
| Revenue, last 12 months | $14.2B |
| Net income, last 12 months | $920M |
| Free cash flow, last 12 months | $1.3B |
| Price to earnings | 11.0× |
| Free cash flow yield | 12.8% |
| Dividend yield | 0.0% |
| Operating margin | 15.0% |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.32 |
| Volatility, annualized | 38.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $3.6B | 4.6% | $3.40 | $359M |
| June 30, 2026 | $3.6B | 5.2% | $4.02 | $320M |
| March 31, 2026 | $3.4B | 6.0% | $2.87 | $219M |
| December 31, 2025 | $3.6B | 9.9% | $3.22 | $395M |
| September 30, 2025 | $3.4B | 4.8% | $2.04 | $675M |
| June 30, 2025 | $3.4B | 6.1% | $2.58 | $203M |
| March 31, 2025 | $3.2B | 5.0% | $2.00 | $37M |
| December 31, 2024 | $3.3B | 4.7% | $3.07 | $377M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $3.85B: Claude 42%, Gemini 40%, Mistral 55%
- Diluted earnings per share are at least $3.22: Claude 58%, Gemini 90%, Mistral 75%
- Free cash flow for the quarter is at least $0.40B: Claude 48%, Gemini 65%, Mistral 60%
11 ledger entries and 48 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.